Commission and EIB provide CureVac with a €75 million financing for vaccine development and expansion of manufacturing
The European Investment Bank (EIB) and CureVac, a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on optimised mRNA, entered into a €75 million loan agreement to support the Company's ongoing development of vaccines against infectious diseases, including its vaccine candidate CVnCoV aimed at preventing SARS-CoV-2 infections. In addition, the loan will support the Company's efforts to expand its existing Good Manufacturing Practice (GMP) certified production capabilities and accelerate the completion of its fourth production site in Tübingen, Germany. The EIB financing will be provided in three €25 million tranches upon completion of pre-defined milestones.
- European Investment Bank and CureVac sign €75 million loan agreement for the development and large-scale production of vaccines, including CureVac's vaccine candidate against SARS-CoV-2
- The EIB loan will support CureVac's activities to complete its new messenger ribonucleic acid (mRNA) production facility in Tübingen, Germany
- The transaction is financed under the Infectious Diseases Finance Facility of Horizon 2020, the EU research and innovation programme for 2014-2020
Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth, yesterday said: “The coronavirus will be with us, as long as we do not have a vaccine against it. This is why our work on this front, together with international actors, is so crucial. Recently we have presented our vaccines strategy to accelerate the development, manufacturing and deployment of vaccines against the novel coronavirus. And since the beginning of the pandemic, we increased the funding for the Infectious Diseases Finance Facility by €400 million to allow the EIB to process a higher volume of projects addressing this disease. With our support to CureVac we accelerate our efforts to find safe and effective solutions for everyone in Europe and globally.”
“It does not need a pandemic to prove that new vaccines can be breakthroughs for public health,” said Ambroise Fayolle, EIB Vice-President in charge of innovation and health. “But in times like ours it becomes clear just how important they are to keep societies running globally. In fact, the only way to end the dramatic situation the world is facing since the outbreak of the COVID-19 pandemic would be a safe and effective vaccine. Thanks to our cooperation with the European Commission, we can finance more and more innovative biotech and medtech companies, such as CureVac, in their research and development of vaccines, therapeutics and diagnostics solutions. This is an added value of Europe, and the EIB does everything it can to maximise this value for the sake of people.”
Pierre Kemula, Chief Financial Officer of CureVac, added: “We are very pleased with the EIB financing. It allows us to further invest in our mRNA technology platform to fight life-threatening diseases. We are working intensively to develop a safe and effective low dose mRNA vaccine against SARS-CoV-2 and started a Phase 1 clinical trial of CVnCoV in June. We are looking forward to expediting the completion of our industrial-scale production site to provide critically needed supply of innovative mRNA-based vaccines.”
About CureVac's mRNA technology platform
CureVac's mRNA technology platform has shown potential in the clinical development and production of mRNA based vaccines and therapeutics. The Company's proprietary RNAoptimizer® platform aims to optimize the properties of mRNA medicines based on its three core pillars: protein design, mRNA optimization and mRNA delivery. The technology can be tailored to induce varying degrees of immune responses against specific protein antigens of choice, potentially providing potent prophylactic vaccines for the prevention of infectious diseases at a low dose, such as Rabies, as well as immunotherapies for the treatment of cancer. The technology can also be adapted to avoid immune activation for purposes of protein therapy and antibodies, thereby providing potential new therapeutic modalities for patients suffering from a vast range of diseases.
The Infectious Diseases Finance Facility (IDFF) of the EU's Horizon 2020 programme backs the loan to CureVac. The IDFF is an example of successful collaboration between the European Commission and the EIB in the face of a health crisis. Through the IDFF, the EIB has supported 13 companies with total lending of €316 million for developing cures, vaccines and diagnostics against various infectious diseases, most prominently the coronavirus.
Latest News from
Declaration of the High Representative on behalf of the EU on the postponement of the Legislative Council elections in Hong Kong04/08/2020 13:25:00
As set out in the Council conclusions of 24 July, the EU is following closely the political situation in Hong Kong and reiterates that it is essential that the Legislative Council elections take place in an environment which is conducive to the exercise of democratic rights and freedoms as enshrined in the Hong Kong’s Basic Law.
Dietary sugars – new date in 2021 for safety assessment04/08/2020 11:33:00
The timing of EFSA’s assessment of the safety of dietary sugars has been revised due to the impact of the COVID-19 pandemic on the review of the exceptionally high volume of scientific information being considered.
Member States' compliance with EU law in 2019: more work needed04/08/2020 10:38:00
The Annual Report on Monitoring the Application of EU Law sets out how the Commission monitored and enforced EU law in 2019, and the performance of Member States in various policy areas.
EBA And ESMA Launch Consultation to Revise Joint Guidelines For Assessing The Suitability of Members of The Management Body And Key Function Holders04/08/2020 09:25:00
The European Banking Authority (EBA) and the European Supervisory Market Authority (ESMA) recently (31 July 2020) launched a public consultation on their revised joint Guidelines.
ESMA Withdraws Registration of NEX Abide Trade Repository AB03/08/2020 16:43:00
The European Securities and Markets Authority (ESMA), the EU's Securities Markets Authority, recently (31 July 2020) withdrew the trade repository (TR) registration of NEX Abide Trade Repository AB (NATR).
Coronavirus: European Commission strengthens support for treatment through convalescent plasma03/08/2020 15:25:00
The European Commission recently (31 July 2020) invited more than 200 blood-collection services around the EU to apply for funding for the purchase of plasmapheresis equipment, i.e. equipment that takes plasma from donors.
Mergers: Commission clears Alstom's acquisition of Bombardier, subject to conditions03/08/2020 14:33:00
The European Commission has approved, under the EU Merger Regulation, the acquisition of Bombardier Transportation by Alstom.
Coronavirus: Commission concludes talks to secure future coronavirus vaccine for Europeans03/08/2020 13:25:00
The European Commission has concluded exploratory talks with a pharmaceutical company to purchase a potential vaccine against COVID-19.
EU-Vietnam trade agreement enters into force03/08/2020 12:48:00
EU exports to Vietnam are now bieng taxed less as of saturday, 1 August. This is the immediate effect of the entry into force of the EU-Vietnam trade agreement that will ultimately scrap duties on 99% of all goods traded between the two sides.
Skills: Five new cross-border collaboration projects selected for Erasmus+ funding to develop excellence in vocational training in Europe31/07/2020 09:25:00
The Commission yesterday proposed Erasmus+ funding for five new Platforms of Centres of Vocational Excellence, to meet the needs of an innovative, inclusive and sustainable economy.